Horizon Discovery Group Plc (HZD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
110
About the Report
About the Report
Summary
Horizon Discovery Group Plc (Horizon Discovery) is a life science company that discovers and develops genetically-modified cell lines using a proprietary translational genomics platform. The company offers products such as cell lines, reference standards and in vivo models. It also offers services such as CRISPR screening, combination screening, in vivo assay services and cell-based assays, among others. Horizon Discovery offers its products and services to genomic research organizations, pharmaceutical, biotechnology and diagnostic companies and academic research centers for the formulation of customized medicines. The company has operations in the UK and the US. Horizon Discovery is headquartered in Cambridge, the UK.
Horizon Discovery Group Plc (HZD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Horizon Discovery Group Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Horizon Discovery Group Plc, Medical Devices Deals, 2012 to YTD 2018 12
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Horizon Discovery Completes Acquisition of Combination High Throughput Screening from Zalicus 17
Venture Financing 18
Horizon Discovery Raises USD 10.5 Million In Final Closing Of Series C Financing 18
Private Equity 20
ValueAct Capital Acquires Additional Stake in Horizon Discovery Group from Woodford Investment Management 20
Partnerships 21
Horizon Discovery Enters into Licensing Agreement for Transposon Based Technology Platform 21
Horizon Discovery Enters Into Licensing Agreement With ATCC 22
Celyad Enters into Agreement with Horizon Discovery 23
Horizon Discovery Enters into Partnership 24
Horizon Discovery Enters into Co-Development Agreement with Roche Diagnostics 25
Horizon Discovery Enters into Research Agreement with Solentim 26
Horizon Discovery Enters into Agreement with Fulcrum Therapeutics 27
Horizon Discovery Enters into Agreement with Ubiquigent 28
Horizon Discovery Forms Joint Venture with Centauri Therapeutics 29
Horizon Discovery Partners with Axol Bioscience 30
Horizon Discovery Enters into Agreement with Swift Biosciences 31
Horizon Discovery Enters into Research Agreement with Redx Pharma 32
Horizon Discovery Enters into Co-Development Agreement with DefiniGEN 33
CareDx Enters into Co-Development Agreement with Horizon Discovery 34
Horizon Discovery Enters into Agreement with Thermo Fisher Scientific 35
Horizon Discovery Enters Into Marketing Agreement With Thermo Fisher 36
Horizon Discovery Enters into Distribution Agreement with Haplogen Genomics 37
Horizon Discovery Enters into Development and Commercialization Agreement with Otsuka Pharma 38
Horizon Discovery Enters Into Co-Development Agreement With Desktop Genetics 39
Crown Bioscience Enters Into Agreement With Horizon Discovery To Develop In Vivo Models For Drug Discovery 40
Horizon Discovery Enters Into R&D Agreement With UCL Institute of Neurology For rAAV-mediated Genome Editing 41
Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 42
Horizon Discovery Enters Into Agreement With Domainex To Support Oncology Program 43
Horizon Discovery Enters Into Co-Development Agreement With Bayer Pharma For Human Isogenic Cell Lines 44
Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine 45
Licensing Agreements 46
Cytovance Biologics Enters into Licensing Agreement with Horizon Discovery 46
Horizon Discovery Enters into Licensing Agreement with US Immuno-Oncology Company 47
ATUM Enters into Licensing Agreement with Horizon Discovery 48
Horizon Discovery Enters into Licensing Agreement with ATUM 49
Horizon Discovery Group Enters into Licensing Agreement with AmplyCell 50
Horizon Discovery Enters into Licensing Agreement with Wistar Institute 51
Horizon Discovery Enters into Licensing Agreement with Servier Lab 52
LakePharma Enters into Licensing Agreement with Horizon Discovery 53
Abcam Enters into Licensing Agreement with Horizon Discovery 54
Horizon Discovery Extends Licensing Agreement with ERS Genomics 55
Horizon Discovery And AstraZeneca Enter Into Licensing Agreement To Develop Cancer Therapies 56
Horizon Discovery Group Enters into Licensing Agreement 58
Horizon Discovery Enters into Licensing Agreement with ProteoNic 59
Horizon Discovery Enters into Licensing Agreement with Stanford University 60
Horizon Discovery Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 61
Horizon Discovery Enters Into Licensing Agreement With AstraZeneca 62
Horizon Discovery Enters Into Licensing Agreement With Harvard University For Crispr Gene Editing Technology 63
Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 64
NIH Center for Regenerative Medicine Enters Into Licensing Agreement With Horizon Discovery For Genesis Technology 65
Horizon Discovery Enters Into Licensing Agreement With Rosalind Franklin University of Medicine and Science 66
Equity Offering 67
Horizon Discovery Raises USD104.6 million in Private Placement of Shares 67
Horizon Discovery Raises USD38.5 Million in Private Placement of Shares 68
Horizon Discovery Completes IPO For USD 66.7 Million 69
Acquisition 71
Horizon Discovery Acquires GE Healthcare Dharmacon from General Electric for USD85 Million 71
Horizon Discovery Acquires Haplogen Genomics for USD15 Million 73
Horizon Discovery Acquires Sage Labs for USD48 Million 74
Horizon Discovery Group Plc-Key Competitors 75
Horizon Discovery Group Plc-Key Employees 76
Horizon Discovery Group Plc-Locations And Subsidiaries 77
Head Office 77
Other Locations & Subsidiaries 77
Joint Venture 78
Recent Developments 79
Financial Announcements 79
Sep 17, 2018: HORIZON DISCOVERY GROUP announce interim results for the six months ended 30 June 2018 79
May 08, 2018: Horizon Discovery Group: Preliminary Results for the Year Ended 31 December 2017 84
Sep 26, 2017: Horizon Discovery Group: Interim Results For The Six Months Ended 30 June 2017 85
May 30, 2017: Horizon Discovery Group: Preliminary Results for the Year Ended 31 December 2016 91
Corporate Communications 92
May 17, 2018: Horizon Discovery: Board Change 92
May 08, 2018: Horizon Discovery appoints Terry Pizzie as Chief Executive Officer 93
Mar 02, 2018: Horizon Discovery Group: Board Change 94
Feb 20, 2018: Horizon Discovery Announces Leadership Changes 95
Legal and Regulatory 96
Jul 03, 2017: Horizon Discovery announces inclusion of its Reference Standards in successful FDA approval of an oncology companion diagnostic test with leading next generation sequencing company 96
Government and Public Interest 97
Jul 17, 2017: Sphere Fluidics and Partners Win Major InnovateUK Grant to Develop the World's First Desktop Genome Editing System 97
May 22, 2017: Horizon Discovery Announces New Gene Editing Technology Platform for Research and Therapeutic Applications 98
Product News 99
Nov 14, 2017: Horizon Discovery's Dharmacon introduces Edit-R CRISPRa reagent platform for genome-wide CRISPR activation 99
Aug 01, 2017: Horizon Discovery announces release of high quality, well annotated CHO genome sequence to drive innovation in bioproduction 100
May 26, 2017: Horizon Discovery introduces four BRAF resistant melanoma PDX models 102
Mar 26, 2018: Horizon Discovery introduces whole human genome arrayed libraries to support CRISPR activation screening 103
Other Significant Developments 104
Sep 14, 2018: Horizon Discovery Edit-R crRNA libraries adopted by AstraZeneca as part of its functional genomics discovery platform 104
Mar 21, 2018: Horizon Discovery's Bioproduction cell line used as part of a successful drug (IND) filing 105
Sep 18, 2017: Horizon Discovery announces launch of Genome-Wide CRISPRi and CRISPRa Screening Services 106
May 09, 2017: Horizon Discovery Announces Update on its Immuno-Oncology Platform including Strong Uptake of Product and Service Offerings 107
Jan 24, 2017: Horizon Discovery Group: Trading Update 108
Jan 13, 2017: International Trade Minister Greg Hands visits fast-growing Cambridge life sciences company 109
Appendix 110
Methodology 110
About GlobalData 110
Contact Us 110
Disclaimer 110
List of Figure
List of Figures
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Horizon Discovery Group Plc, Medical Devices Deals, 2012 to YTD 2018 12
List of Table
List of Tables
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Horizon Discovery Group Plc, Deals By Therapy Area, 2012 to YTD 2018 11
Horizon Discovery Group Plc, Medical Devices Deals, 2012 to YTD 2018 12
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Horizon Discovery Completes Acquisition of Combination High Throughput Screening from Zalicus 17
Horizon Discovery Raises USD 10.5 Million In Final Closing Of Series C Financing 18
ValueAct Capital Acquires Additional Stake in Horizon Discovery Group from Woodford Investment Management 20
Horizon Discovery Enters into Licensing Agreement for Transposon Based Technology Platform 21
Horizon Discovery Enters Into Licensing Agreement With ATCC 22
Celyad Enters into Agreement with Horizon Discovery 23
Horizon Discovery Enters into Partnership 24
Horizon Discovery Enters into Co-Development Agreement with Roche Diagnostics 25
Horizon Discovery Enters into Research Agreement with Solentim 26
Horizon Discovery Enters into Agreement with Fulcrum Therapeutics 27
Horizon Discovery Enters into Agreement with Ubiquigent 28
Horizon Discovery Forms Joint Venture with Centauri Therapeutics 29
Horizon Discovery Partners with Axol Bioscience 30
Horizon Discovery Enters into Agreement with Swift Biosciences 31
Horizon Discovery Enters into Research Agreement with Redx Pharma 32
Horizon Discovery Enters into Co-Development Agreement with DefiniGEN 33
CareDx Enters into Co-Development Agreement with Horizon Discovery 34
Horizon Discovery Enters into Agreement with Thermo Fisher Scientific 35
Horizon Discovery Enters Into Marketing Agreement With Thermo Fisher 36
Horizon Discovery Enters into Distribution Agreement with Haplogen Genomics 37
Horizon Discovery Enters into Development and Commercialization Agreement with Otsuka Pharma 38
Horizon Discovery Enters Into Co-Development Agreement With Desktop Genetics 39
Crown Bioscience Enters Into Agreement With Horizon Discovery To Develop In Vivo Models For Drug Discovery 40
Horizon Discovery Enters Into R&D Agreement With UCL Institute of Neurology For rAAV-mediated Genome Editing 41
Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 42
Horizon Discovery Enters Into Agreement With Domainex To Support Oncology Program 43
Horizon Discovery Enters Into Co-Development Agreement With Bayer Pharma For Human Isogenic Cell Lines 44
Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine 45
Cytovance Biologics Enters into Licensing Agreement with Horizon Discovery 46
Horizon Discovery Enters into Licensing Agreement with US Immuno-Oncology Company 47
ATUM Enters into Licensing Agreement with Horizon Discovery 48
Horizon Discovery Enters into Licensing Agreement with ATUM 49
Horizon Discovery Group Enters into Licensing Agreement with AmplyCell 50
Horizon Discovery Enters into Licensing Agreement with Wistar Institute 51
Horizon Discovery Enters into Licensing Agreement with Servier Lab 52
LakePharma Enters into Licensing Agreement with Horizon Discovery 53
Abcam Enters into Licensing Agreement with Horizon Discovery 54
Horizon Discovery Extends Licensing Agreement with ERS Genomics 55
Horizon Discovery And AstraZeneca Enter Into Licensing Agreement To Develop Cancer Therapies 56
Horizon Discovery Group Enters into Licensing Agreement 58
Horizon Discovery Enters into Licensing Agreement with ProteoNic 59
Horizon Discovery Enters into Licensing Agreement with Stanford University 60
Horizon Discovery Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 61
Horizon Discovery Enters Into Licensing Agreement With AstraZeneca 62
Horizon Discovery Enters Into Licensing Agreement With Harvard University For Crispr Gene Editing Technology 63
Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 64
NIH Center for Regenerative Medicine Enters Into Licensing Agreement With Horizon Discovery For Genesis Technology 65
Horizon Discovery Enters Into Licensing Agreement With Rosalind Franklin University of Medicine and Science 66
Horizon Discovery Raises USD104.6 million in Private Placement of Shares 67
Horizon Discovery Raises USD38.5 Million in Private Placement of Shares 68
Horizon Discovery Completes IPO For USD 66.7 Million 69
Horizon Discovery Acquires GE Healthcare Dharmacon from General Electric for USD85 Million 71
Horizon Discovery Acquires Haplogen Genomics for USD15 Million 73
Horizon Discovery Acquires Sage Labs for USD48 Million 74
Horizon Discovery Group Plc, Key Competitors 75
Horizon Discovery Group Plc, Key Employees 76
Horizon Discovery Group Plc, Other Locations 77
Horizon Discovery Group Plc, Subsidiaries 77
Horizon Discovery Group Plc, Joint Venture 78
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.